| Bioactivity | Eflapegrastim is a humanized IgG4 monoclonal antibody, is also a granulocyte colony-stimulating factor (G-CSF). Eflapegrastim targets to G-CSF receptor (c-Fms). Eflapegrastim stimulates proliferation and differentiation of neutrophil progenitor cells and maintains stable numbers of mature and functional neutrophils. Eflapegrastim also shortens the duration of neutropenia[1]. |
| Invitro | Eflapegrastim 含有 IgG4 Fc 片段和短聚乙二醇连接物[1]。Eflapegrastim (5.5-88 mM; 4 min) 与 FcRn 结合，但不与 Fcγ 受体或 C1q 结合[1]。Eflapegrastim (0.000036-0.709 nmol/L; 54 h) 诱导骨髓细胞增殖[1]。Eflapegrastim (10 μM; 1 h) 结合FcRn并经历FcRn介导的胞吞作用[1]。 |
| In Vivo | Eflapegrastim (100 μg/kg; 皮下注射; 单次剂量) 降低化疗诱导的中性粒细胞减少大鼠中性粒细胞减少 (DN) 的持续时间，增加血清和骨髓中 G-CSF 的水平[1]。 Animal Model: |
| Name | Eflapegrastim |
| CAS | 1384099-30-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Barrett JA, et al. Eflapegrastim's enhancement of efficacy compared with pegfilgrastim in neutropenic rats supports potential for same-day dosing. Exp Hematol. 2020 Dec;92:51-61. |